Key Points
- CEO Martine Rothblatt sold 4,000 shares of United Therapeutics on Nov. 25 at an average price of $475.33 for about $1.90 million, leaving her with 130 shares (a 96.85% reduction), per the SEC filing.
- United Therapeutics beat EPS expectations in Q3 with $7.16 vs. $6.89 consensus but posted revenue of $799.5M slightly below estimates; the stock trades near $485 and carries a consensus analyst rating of “Moderate Buy” with a $505 average price target.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of United Therapeutics stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $475.33, for a total transaction of $1,901,320.00. Following the completion of the sale, the chief executive officer owned 130 shares in the company, valued at approximately $61,792.90. This trade represents a 96.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
United Therapeutics Trading Up 1.8%
NASDAQ:UTHR opened at $485.77 on Wednesday. The stock has a 50 day moving average of $443.02 and a two-hundred day moving average of $358.73. The firm has a market cap of $20.92 billion, a P/E ratio of 18.41, a price-to-earnings-growth ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $486.20.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same period in the prior year, the company earned $6.39 EPS. The firm's revenue was up 6.8% compared to the same quarter last year. On average, research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Analysts Set New Price Targets
A number of research firms have recently issued reports on UTHR. Jefferies Financial Group restated a "buy" rating and issued a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. Oppenheimer upped their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a report on Friday, September 5th. Weiss Ratings restated a "buy (b-)" rating on shares of United Therapeutics in a report on Wednesday, November 19th. Cantor Fitzgerald raised their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a research report on Wednesday, September 10th. Finally, Bank of America boosted their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a report on Tuesday, September 2nd. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $505.00.
Get Our Latest Stock Report on United Therapeutics
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in UTHR. Wilmington Savings Fund Society FSB boosted its holdings in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock valued at $37,000 after acquiring an additional 49 shares during the period. Chung Wu Investment Group LLC purchased a new stake in United Therapeutics in the 2nd quarter valued at $29,000. Abich Financial Wealth Management LLC purchased a new stake in United Therapeutics in the 3rd quarter valued at $44,000. SVB Wealth LLC acquired a new stake in United Therapeutics during the 1st quarter worth $32,000. Finally, WealthCollab LLC grew its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
